Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Conditions: T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoma; Mixed Phenotype Acute Leukemia Interventions: Drug: Dexamethasone; Drug: Vincristine; Drug: Daunorubicin; Drug: Calaspargase pegol; Drug: Dasatinib; Drug: Venetoclax; Drug: Bortezomib; Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine); Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Mercaptopurine; Drug: Nelarabine; Drug: Methotrexate; Drug: Thioguanine Sponsors: St. Jude Children ' s Research Hospital; AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials